Novo Nordisk | NVO - Sales Revenues


Novo Nordisk reported DKK12.13B in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
ANI Pharmaceuticals USD 266M 28.5M Jun/2026
Aurora Cannabis CAD 38.01M 56.18M Mar/2026
Bausch Health Companies USD 2.85B 350M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Canopy Growth CAD 71.25M 3.29M Mar/2026
Corcept Therapeutics USD 256.15M 91.25M Jun/2026
Drreddys Laboratories INR 789.05M 86.48B Mar/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Merck USD 16.6B 310M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 14.41B 1.3B Jun/2026
Novo Nordisk DKK 78.49B 18.33B Jun/2026
Novo Nordisk DKK 12.13B 84.69B Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
Perrigo USD 1.02B 51M Jun/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 265.71M 15.91M Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
Supernus Pharmaceuticals USD 219.1M 11.39M Jun/2026
Zoetis USD 2.5B 200M Jun/2026